Proactive - Interviews for investors

CytoDyn says Brazil has approved a Phase 3 trial of its drug in critically ill coronavirus patients

Episode Summary

CytoDyn Inc's Nader Pourhassan tells Proactive that Brazil’s regulatory authority Agência Nacional de Vigilância Sanitária (ANVISA) has approved the start of an additional Phase 3 CD16 clinical trial of its flagship drug leronlimab to treat critically ill coronavirus patients. Pourhassan says the new clinical trial will focus on hospitalized COVID-19 patients in critical condition who require mechanical and invasive ventilation or Extracorporeal Membrane Oxygenation (ECMO).